Schizophrenia: Treatment resistant Psychosis

***SALE PRICE £138.75***

Around a third of patients with schizophrenia are resistant to treatment and the only evidence based treatment for this group is the anti-psychotic, clozapine. Clozapine is a difficult drug to use and some patients do not tolerate it or fail to respond. In this situation the evidence base becomes very thin and the guidelines run out of advice. This multi-speaker event, chaired by Prof James H MacCabe, Kings College London, are Consultant Psychiatrists at the National Psychosis Service, a national service for treatment resistant psychosis. Between them they have decades of clinical experience in the management of TRS and the use of clozapine. In addition, they are all involved at various levels in leading research to consolidate the evidence base in this area.

After attending this course delegates will be able to:

1) Consolidate their knowledge in the management of treatment resistant psychosis

2) Gain confidence in prescribing clozapine in different situations

3) Learn of some of the latest research in the field